Follow
Christian Reinhardt
Christian Reinhardt
University Duisburg-Essen, University Hospital Essen
Verified email at uk-essen.de - Homepage
Title
Cited by
Cited by
Year
Comprehensive genomic profiles of small cell lung cancer
J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ...
Nature 524 (7563), 47-53, 2015
19532015
p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
HC Reinhardt, AS Aslanian, JA Lees, MB Yaffe
Cancer cell 11 (2), 175-189, 2007
7262007
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
HC Reinhardt, MB Yaffe
Current opinion in cell biology 21 (2), 245-255, 2009
6242009
The p53 network: cellular and systemic DNA damage responses in aging and cancer
HC Reinhardt, B Schumacher
Trends in Genetics 28 (3), 128-136, 2012
5492012
The combined status of ATM and p53 link tumor development with therapeutic response
H Jiang, HC Reinhardt, J Bartkova, J Tommiska, C Blomqvist, ...
Genes & development 23 (16), 1895-1909, 2009
3472009
Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels
TB Huber, B Schermer, RU Müller, M Höhne, M Bartram, A Calixto, ...
Proceedings of the National Academy of Sciences 103 (46), 17079-17086, 2006
3442006
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
F Dietlein, L Thelen, HC Reinhardt
Trends in genetics 30 (8), 326-339, 2014
3052014
A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint
MATM van Vugt, AK Gardino, R Linding, GJ Ostheimer, HC Reinhardt, ...
PLoS biology 8 (1), e1000287, 2010
2862010
Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response
HC Reinhardt, MB Yaffe
Nature reviews Molecular cell biology 14 (9), 563-580, 2013
2822013
14-3-3σ controls mitotic translation to facilitate cytokinesis
EW Wilker, MATM Van Vugt, SC Artim, PH Huang, CP Petersen, ...
Nature 446 (7133), 329-332, 2007
2822007
DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization
HC Reinhardt, P Hasskamp, I Schmedding, S Morandell, MATM van Vugt, ...
Molecular cell 40 (1), 34-49, 2010
2712010
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
CD Herling, N Abedpour, J Weiss, A Schmitt, RD Jachimowicz, O Merkel, ...
Nature communications 9 (1), 727, 2018
2022018
NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway
S Habbig, MP Bartram, RU Müller, R Schwarz, N Andriopoulos, S Chen, ...
Journal of Cell Biology 193 (4), 633-642, 2011
1722011
Expression of functional CCR and CXCR chemokine receptors in podocytes
TB Huber, HC Reinhardt, M Exner, JA Burger, D Kerjaschki, MA Saleem, ...
The Journal of Immunology 168 (12), 6244-6252, 2002
1592002
Exploiting synthetic lethal interactions for targeted cancer therapy
HC Reinhardt, H Jiang, MT Hemann, MB Yaffe
Cell cycle 8 (19), 3112-3119, 2009
1472009
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy
CD Herling, M Klaumünzer, CK Rocha, J Altmüller, H Thiele, J Bahlo, ...
Blood, The Journal of the American Society of Hematology 128 (3), 395-404, 2016
1462016
KIBRA modulates directional migration of podocytes
K Duning, EM Schurek, M Schlu, M Bayer, HC Reinhardt, A Schwab, ...
Journal of the American Society of Nephrology 19 (10), 1891-1903, 2008
1352008
Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
L Meder, P Schuldt, M Thelen, A Schmitt, F Dietlein, S Klein, S Borchmann, ...
Cancer research 78 (15), 4270-4281, 2018
1342018
A synergistic interaction between Chk1-and MK2 inhibitors in KRAS-mutant cancer
F Dietlein, B Kalb, M Jokic, EM Noll, A Strong, L Tharun, L Ozretić, ...
Cell 162 (1), 146-159, 2015
1332015
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
J Fassunke, F Müller, M Keul, S Michels, MA Dammert, A Schmitt, ...
Nature communications 9 (1), 4655, 2018
1282018
The system can't perform the operation now. Try again later.
Articles 1–20